Clinical Trial Update: Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating platinum-based chemoradiotherapy with rigosertib for head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 1 | Status: COMPLETED